A Phase 3 trial evaluating a combination of the checkpoint antibody Tecentriq (atezolizumab) and the kinase inhibitor Cotellic (cobimetinib) in patients with metastatic colorectal cancer failed to meet its primary endpoint of overall survival, Roche announced on 10 May.
